Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is projected to experience significant revenue growth, with a forecasted increase of over 20% annually through 2026, driven by the commercial success of products like Vabysmo, Ojemda, and Miplyffa. In 2024, XOMA reported total income and revenues from royalty agreements of $28.5 million, a substantial rise from $4.8 million in the previous year, highlighting the effectiveness of both acquisitions and internal growth strategies. Looking forward, the company anticipates generating $49.0 million in revenues for 2026, a notable 36% increase over 2025, supported by both existing commercial-stage assets and potential milestone payments from earlier-stage assets assuming positive clinical progress.

Bears say

XOMA Royalty Corp has experienced revenue and net earnings variability attributed to its operations in the fluctuating international market, which is susceptible to economic downturns, new tariffs, and changes in governmental reimbursement policies. The company’s reliance on external partnerships for future economic rights poses significant risks, as any adverse developments, including failed clinical trials or funding challenges, could impede its drug development pipeline and overall operational stability. Furthermore, recent declines in the company's stock performance following pandemic-related highs highlight the volatility inherent in the biotechnology sector, exacerbated by potential leadership turnover that may compromise institutional knowledge and strategic direction.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.